Docoh
Loading...

BSTC Biospecifics Technologies

BioSpecifics Technologies Corp. engages in the development of an injectable collagenase clostridium histolyticum for multiple indications. It sells its products under the brand XIAFLEX. The company was founded in 1990 and is headquartered in Lynbrook, NY.

Company profile

Ticker
BSTC
Exchange
CEO
Joseph Truitt
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
113054851

BSTC stock data

(
)

Calendar

9 Nov 20
27 Jul 21
31 Dec 21
Quarter (USD)
Sep 20 Jun 20 Mar 20 Sep 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 19 Dec 18 Dec 17 Dec 16
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 2.87M 2.87M 2.87M 2.87M 2.87M 2.87M
Cash burn (monthly) 4.67M 924.9K (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) 46.28M 9.17M n/a n/a n/a n/a
Cash remaining -43.4M -6.3M n/a n/a n/a n/a
Runway (months of cash) -9.3 -6.8 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
2 Dec 20 Schamroth Michael Common Stock, $0.001 par value Sale back to company Dispose D No No 0 1,726 0 0
2 Dec 20 Schamroth Michael Common Stock, $0.001 par value Sale back to company Dispose D No No 0 115,890 0 1,726
2 Dec 20 Truitt Joseph Stock Option Common Stock Sale back to company Dispose D No No 24.78 100,000 2.48M 0
2 Dec 20 Gitman Paul Common Stock, $0.001 par value Sale back to company Dispose D No No 0 1,726 0 0
2 Dec 20 Gitman Paul Common Stock, $0.001 par value Sale back to company Dispose D No No 0 16,890 0 1,726
2 Dec 20 Patrick Hutchison Stock Option Common Stock Sale back to company Dispose D No No 32.29 10,000 322.9K 0
2 Dec 20 Sherman Michael A. Common Stock, $0.001 par value Sale back to company Dispose D No No 0 2,018 0 0
2 Dec 20 Sherman Michael A. Stock Option Common Stock Sale back to company Dispose D No No 32.87 6,000 197.22K 0

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

0.0% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1 1
Opened positions 0 1 EXIT
Closed positions 0 112 EXIT
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 100 100
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
ENDP Endo International 100 $0 0.0%
Largest transactions
Shares Bought/sold Change
ENDP Endo International 100 0 0.0%
Renaissance Technologies 0 0
Rice Hall James & Associates 0 0
Wegman Toby 0 0
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: abroad, absence, absent, acquisition, advisory, al, alter, antitrust, appraisal, asserted, assumption, ATM, attention, attorney, attractive, automatically, Beta, captioned, certainty, committed, competent, competing, complaint, consummate, consummated, consummating, consummation, contemplated, converted, Court, coverage, customary, deal, deciding, deemed, defense, delivery, detrimental, devoted, distraction, District, diversion, divert, diverting, divestiture, drop, enjoin, expert, focusing, foregoing, foreign, forward, fulfill, heighten, holder, HSR, impression, inapplicable, incomplete, indemnification, indirect, injunctive, integrating, Ireland, irrevocably, lawsuit, light, maximum, merge, merit, ministry, mitigate, motivate, notwithstanding, omission, Oppenheimer, opportunistic, Owner, Parent, pendency, pending, Plaintiff, practice, printing, proceeding, prohibiting, promulgated, properly, purported, purportedly, purpose, pursuing, recovery, recruit, redirecting, relationship, renew, rescission, rescissory, retain, satisfactory, Shiva, spring, Stein, Stifel, stockholder, supplemented, survive, surviving, temperature, timeframe, unable, unanticipated, undertaken, valid, validly, violation, vote, waiting, waived, waiver, weather, welfare, wholly, withholding, worsen, wrongdoing, xi, xii
Removed: analyze, buy, consumed, content, demonstrating, design, discount, Dr, Employment, estimating, finite, forecast, France, Gelbard, guide, half, inform, initial, intend, Investigation, Martin, pattern, Phase, positive, premium, proportion, Reproductive, Society, unamortized

Patents

APP
Utility
Treatment Method and Product for Uterine Fibroids using Purified Collagenase
22 Jul 21
The invention relates to compositions and methods for treating uterine fibroids, wherein a uterine fibroid treatment agent comprising collagenase in an amount effective to cause shrinkage of uterine fibroids is injected or inserted into the uterine fibroid.
APP
Utility
Treatment of Uterine Fibroids using Purified Collagenase
22 Apr 21
The invention relates to compositions and methods for treating uterine fibroids in vivo, wherein a uterine fibroid treatment agent comprising collagenase in an amount effective to cause shrinkage and/or reduce stiffness of uterine fibroids is injected or inserted into the uterine fibroid.
APP
Utility
Thermosensitive Hydrogel Collagenase Formulations
4 Mar 21
It is an object of the present disclosure to provide a formulation for injectable and topical collagenase, which will have extended residence time for the drug at the therapeutic targeted area for the indication being treated.
APP
Utility
Compositions and Methods for Producing Clostridial Collagenases
11 Feb 21
The present invention provides a method for producing a drug product comprising a combination of highly purified collagenase I and collagenase II from Clostridium histolyticum.
APP
Utility
Treatment Method and Product for Uterine Fibroids using Purified Collagenase
28 Jan 21
The invention relates to compositions and methods for treating uterine fibroids, wherein a uterine fibroid treatment agent comprising collagenase in an amount effective to cause shrinkage of uterine fibroids is injected or inserted into the uterine fibroid.